Campaigners welcome Nice approval for use of Kimmtrak (tebentafusp) to treat patients with uveal melanoma
Hundreds of patients in England with a rare form of eye cancer are to be offered on the NHS a pioneering drug that kills cancer cells and boosts the chances of survival.
In guidance published on Tuesday, the National Institute for Health and Care Excellence (Nice) gave the green light to tebentafusp for patients whose uveal melanoma cannot be removed with surgery or has spread to other parts of the body.
